sar425899 sanofi glp-1 glucagon dual agonist The molecular pharmacology of agonists in diabetes and obesity Effects on weight loss and
Description
The synergistic enhancement theory proposes that GIP and GLP-1 dont just add to each other but actually amplify each others effects

doi: 10.1038/nm.2513

Flint A, Kapitza C, Hindsberger C, Zdravkovic M

INTRODUCTION In patients with type 2 diabetes with overweight and no cardiovascular disease or moderate risk of cardiovascular disease, metformin is the recommended initial treatment (class IIa recommendation)

If youre currently taking or considering a GLP-1 medication, understanding these potential long-term risks, especially those affecting bone health, could be crucial for protecting your overall wellness for years to come
